Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, announced that the Company presented clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV in patients with chronic Hepatitis B. The data was presented at the International Coalition to Eliminate HBV (ICE-HBV) “HBV Cure Symposium” Meeting in Berlin, Germany, on September 12th.
Health Technology Insights: Madaket Health Appoints Megan Schmidt as Chief Executive Officer
“We are excited to present the progress for the ELIMINATE-B trial with the HBV community at this year’s ICE-HBV symposium following our data update on August 6th,” said Cassie Gorsuch, PhD, Chief Scientific Officer at Precision BioSciences. “We believe the clinical profile we have observed so far demonstrates the first evidence of substantial HBsAg reductions by a novel therapeutic approach designed to directly target cccDNA for elimination and inactivate integrated HBV DNA in patients with chronic Hepatitis B. In the ELIMINATE-B trial following multiple administrations across two dose levels (Cohort 1 and Cohort 2), PBGENE-HBV has been well-tolerated and active. With the recent initiation of dosing patients in Cohort 3, we remain on track to provide further data updates in 2025.”
Health Technology Insights: University Hospitals Teams with Hippocratic AI for Patient Care
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
